Feuerstein's Biotech Mailbag

Is a weekly column on biotech stocks, usually worth a read.  I found this part interesting:  

I mock Lexicon Genetics, er, Pharmaceuticals, but in all seriousness, why did this rejuvenation take so long? Human Genome Sciences (HGSI - Cramer's Take - Stockpickr - Rating) and Millennium Pharmaceuticals (MLNM - Cramer's Take - Stockpickr - Rating) learned the painful lesson years ago that spending your days poking around human DNA might be noble work, but it certainly wasn't a viable business model. The real money is in developing, and hopefully selling, drugs.